SLE - Rituximab in lupus

被引：32

作者：

Eisenberg, R ^{[1
]}

机构：

[1] Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA

来源：

ARTHRITIS RESEARCH & THERAPY | 2003年 / 5卷 / 04期

关键词：

B cells; CD20; rituximab; systemic lupus erythematosus;

D O I：

10.1186/ar759

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

B cells are essential to the development of systemic lupus erythematosus (SLE). The chimeric monoclonal antibody rituximab depletes B cells by targeting the pan-B-cell surface marker CD20. Preliminary experience with this agent in SLE and other autoimmune diseases has been encouraging. Controlled trials in SLE will be necessary to determine whether rituximab is useful therapy in this disease, and will teach us more about the roles of B cells in its pathogenesis.

引用

页码：157 / 159

页数：3

共 31 条

[1]

Anolik JH, 2002, ARTHRITIS RHEUM-US, V46, pS289

[2]

Cambridge G, 2002, ARTHRITIS RHEUM-US, V46, pS506

[3]

Chan OTM, 1999, J IMMUNOL, V163, P3592

[4] The central and multiple roles of B cells in lupus pathogenesis [J].